Related Experiment Video

Updated: Jul 3, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16

Yvonne M Schrage1, Suzanne Lam, Aart G Jochemsen

  • 1Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.

Journal of Cellular and Molecular Medicine
|July 16, 2008
PubMed

Insights

Targeting the pRb pathway in chondrosarcoma by overexpressing CDKN2A/p16 and inhibiting CDK4 significantly reduced tumor cell growth. This highlights CDK4 inhibitors as a potential therapy for advanced chondrosarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Chondrosarcomas are resistant to conventional treatments, leaving surgery as the only curative option.
  • Inoperable or metastatic chondrosarcoma presents a significant unmet medical need.
  • The pRb pathway is crucial for cell cycle regulation and a potential therapeutic target.

Purpose of the Study:

  • To investigate cell cycle control genes (CDK4, CDKN2A/p16, cyclin D1, p21, p53, MDM2, c-MYC) in chondrosarcoma.
  • To evaluate the therapeutic potential of targeting the pRb pathway in chondrosarcoma cell lines.
  • To correlate gene expression with clinical outcomes in chondrosarcoma patients.

Main Methods:

  • Chondrosarcoma cell lines (OUMS27, SW1353, CH2879) were treated with CDKN2A/p16 overexpression vectors and CDK4 shRNA.
  • Cell viability, proliferation, and colony formation were assessed.
  • Quantitative PCR (qPCR) and immunohistochemistry (IHC) were used to analyze gene expression in patient samples.

Main Results:

  • CDKN2A/p16 overexpression and CDK4 knockdown significantly decreased chondrosarcoma cell viability, proliferation, and colony formation.
  • Elevated CDK4 and MDM2 expression correlated with high-grade chondrosarcoma at both mRNA and protein levels.
  • A majority of high-grade chondrosarcomas (96%) showed alterations in the pRb pathway, including cyclin D1 expression and CDKN2A/p16 loss.

Conclusions:

  • Targeting the pRb pathway, specifically via CDK4 inhibition, demonstrates significant anti-proliferative effects in chondrosarcoma.
  • CDK4 and MDM2 are potential biomarkers for high-grade chondrosarcoma.
  • CDK4 inhibitors represent a promising therapeutic strategy for inoperable or metastatic high-grade chondrosarcoma.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...